Exopharm Competitors and Similar CompaniesClear all

Exopharm's competitors and similar companies include Lexicon Pharmaceuticals, Ionis Pharmaceuticals and CRISPR Therapeutics.

	Exopharm Exopharm is a biopharmaceutical company that specializes in the development of genetic medicines.	Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.	CRISPR Therapeutics CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases.
Founding Date	Founding Date 2013	Founding Date 1995	Founding Date 1989	Founding Date 2013
Type	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech drug development genetics pharma
Locations	Locations HQ	Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more	Locations Carlsbad, US HQ Vancouver, CA Stuttgart, DE Dublin, IE Dublin, IE Lisboa, PT London, GB see more	Locations Zug, CH HQ Greater London, GB Cambridge, US San Francisco, US
Employees	Employees N/A	Employees 20216% increase	Employees 1,40231% increase	Employees 393
Valuation ($)	Valuation ($) 1.3 m	Valuation ($) 737.4 m	Valuation ($) 6.3 b	Valuation ($) 4.2 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $49.8m (FY, 2025)	Revenue (est.) $943.7m (FY, 2025)	Revenue (est.) $3.5m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $274k (FY, 2025)	Cost of goods $15.9m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit $1.6m (FY, 2025)	Gross profit $49.5m (FY, 2025)	Gross profit $927.8m (FY, 2025)	Gross profit N/A
Net income	Net income ($5.3m) (FY, 2025)	Net income ($50.3m) (FY, 2025)	Net income ($381.4m) (FY, 2025)	Net income ($581.6m) (FY, 2025)
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 1 (FY, 2016)	Phase I Trials Products 1 (FY, 2023)	Phase I Trials Products N/A
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 2 (FY, 2016)	Phase III Trials Products 17 (FY, 2024)	Phase III Trials Products N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 244.7m	Total funding raised N/A	Total funding raised $ 127m